NCT06611657View on ClinicalTrials.gov

Antirotinib Hydrochloride Plus Whole Brain Radiotherapy for Small Cell Lung Cancer With Brain Metastases

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 20, 2021

Primary Completion Date

June 10, 2024

Study Completion Date

July 30, 2025

Conditions
Whole Brain Radiotherapy
Interventions
DRUG

Antirotinib hydrochloride

Oral antirotinib treatment was started 2 weeks before radiotherapy for brain metastases, stopped for 1 week after 2 weeks, and continued after radiotherapy until tumor progression

Trial Locations (1)

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER